PDF(Pubmed)
Abstract：
UNASSIGNED: Solid organ transplant recipients are at high risk for developing severe zoster-associated neuralgia, and the pharmaceutic therapies of pain management for these patients with limited organ function are challenging. Intravenous lidocaine infusion showed positive analgesic effects and is used for the management of neuropathic pain. This case series reports the safety and effectiveness of intravenous lidocaine infusion in the treatment of intractable zoster-associated neuralgia in solid organ transplant recipients.
UNASSIGNED: Five solid organ transplant recipients suffering from refractory zoster-associated neuralgia (numeric rating scale 8-10, despite using high doses of antiepileptic drugs or combined with opioids) were enrolled. Intravenous lidocaine (5 mg/kg ideal bodyweight) was administered over 1.5 h with the monitoring of vital signs. Pain intensity, patient satisfaction, adverse events, typical liver, and kidney function were evaluated. All subjects reported high satisfaction with their treatment and effective pain relief at the 6-month follow-up. One patient experienced short and mild numbness in the mouth and dizziness after the therapy, but no major adverse reactions were reported.
UNASSIGNED: This case series provides evidence that intravenous lidocaine infusion provided effective pain relief as an analgesic treatment option for transplant patients with intractable zoster-associated neuralgia.
UNASSIGNED: Five solid organ transplant recipients suffering from refractory zoster-associated neuralgia (numeric rating scale 8-10, despite using high doses of antiepileptic drugs or combined with opioids) were enrolled. Intravenous lidocaine (5 mg/kg ideal bodyweight) was administered over 1.5 h with the monitoring of vital signs. Pain intensity, patient satisfaction, adverse events, typical liver, and kidney function were evaluated. All subjects reported high satisfaction with their treatment and effective pain relief at the 6-month follow-up. One patient experienced short and mild numbness in the mouth and dizziness after the therapy, but no major adverse reactions were reported.
UNASSIGNED: This case series provides evidence that intravenous lidocaine infusion provided effective pain relief as an analgesic treatment option for transplant patients with intractable zoster-associated neuralgia.
摘要：
■实体器官移植受者发生严重带状疱疹相关神经痛的风险很高，对于这些器官功能有限的患者，疼痛管理的药物疗法具有挑战性。静脉输注利多卡因显示出积极的镇痛作用，并用于治疗神经性疼痛。本病例系列报告了静脉输注利多卡因治疗实体器官移植受者顽固性带状疱疹相关神经痛的安全性和有效性。
■纳入了5名患有难治性带状疱疹相关神经痛的实体器官移植受者（数字评定量表8-10，尽管使用了高剂量的抗癫痫药物或与阿片类药物联合使用）。静脉注射利多卡因（5mg/kg理想体重）超过1.5h，并监测生命体征。疼痛强度,患者满意度,不良事件,典型的肝脏,并评估肾功能。所有受试者在6个月的随访中报告了对他们的治疗和有效疼痛缓解的高满意度。一名患者在治疗后出现短暂和轻度的口腔麻木和头晕，但未报告重大不良反应.
■本病例系列提供证据表明，静脉输注利多卡因可有效缓解疼痛，作为难治性带状疱疹相关神经痛的移植患者的镇痛治疗选择。
■纳入了5名患有难治性带状疱疹相关神经痛的实体器官移植受者（数字评定量表8-10，尽管使用了高剂量的抗癫痫药物或与阿片类药物联合使用）。静脉注射利多卡因（5mg/kg理想体重）超过1.5h，并监测生命体征。疼痛强度,患者满意度,不良事件,典型的肝脏,并评估肾功能。所有受试者在6个月的随访中报告了对他们的治疗和有效疼痛缓解的高满意度。一名患者在治疗后出现短暂和轻度的口腔麻木和头晕，但未报告重大不良反应.
■本病例系列提供证据表明，静脉输注利多卡因可有效缓解疼痛，作为难治性带状疱疹相关神经痛的移植患者的镇痛治疗选择。
